DEF: Rapport Therapeutics Sets 2026 Annual Meeting Date

Rapport Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, to elect directors and ratify auditor appointment.

Summary

• Rapport Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders on June 10, 2026, at 1:00 p.m. Eastern Time, via a virtual webcast.
• The meeting's primary purposes include electing three Class II Directors: James Healy, M.D., Ph.D., Robert J. Perez, and Raymond Sanchez, M.D., to serve until the 2029 annual meeting.
• Stockholders will also vote to ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The record date for determining stockholders entitled to vote is April 14, 2026.
• Proxy materials will be made available online, with a Notice of Internet Availability of Proxy Materials to be mailed around April 23, 2026.
• Stockholders can vote online, by phone, or by mail prior to the meeting, or virtually during the meeting.
• The company is an emerging growth company and has utilized reduced disclosure requirements.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine proxy statement for an annual meeting and does not contain new financial performance data or strategic updates.

Positives

• The company is holding its annual meeting as scheduled, indicating ongoing operational and governance processes.
• The slate of directors proposed for election includes individuals with extensive experience in the biopharmaceutical and investment sectors.
• The company continues to engage with its independent auditor, PricewaterhouseCoopers LLP, suggesting a commitment to financial transparency.
• The virtual meeting format allows for broader stockholder participation regardless of location.

Risks

• The filing does not contain specific financial performance data or forward-looking statements that would indicate operational risks.
• As an emerging growth company, Rapport Therapeutics is subject to reduced disclosure requirements, which may limit the depth of information available to investors.

Future Outlook

The filing is a proxy statement and does not contain specific forward-looking financial guidance. It outlines the agenda for the upcoming annual meeting, including the election of directors and ratification of the auditor.

Management Comments

• We are pleased to notify you that we will hold the 2026 annual meeting of our stockholders (the Annual Meeting) on June 10, 2026, at 1:00 p.m., Eastern Time, in a virtual meeting format, which will be conducted via live webcast.
• Your vote is important. Whether you plan to attend the Annual Meeting or not, it is important that your shares be represented.
• We encourage you to vote by proxy so that your shares will be represented and voted at the Annual Meeting, whether or not you can attend.
• Thank you for your continued support of Rapport Therapeutics, Inc.

Industry Context

StockSavvy.ai notes that Rapport Therapeutics, Inc. is operating within the biopharmaceutical sector, a field characterized by significant R&D investment, regulatory oversight, and a focus on corporate governance as companies mature towards commercialization. The scheduling of an annual meeting and the election of directors are standard governance practices for publicly traded companies in this industry.

Management Changes

Corporate Governance

Related Party Transactions

• Purchases of Series B convertible preferred stock by entities affiliated with ARCH Venture Fund XII, L.P., Cormorant Asset Management, LP, Fidelity, Sofinnova Venture Partners XI, L.P., and Third Rock Ventures VI, L.P. between August 2023 and March 2024.
• Purchases of common stock by entities affiliated with Cormorant Asset Management, LP, Fidelity, and Sofinnova in the June 2024 initial public offering.
• Purchase of common stock by Sofinnova in the concurrent private placement in June 2024.
• Purchases of common stock by entities affiliated with Capital Research and Management Company, Cormorant Asset Management, LP, and Fidelity in the September 2025 underwritten public offering.
• The Option and License Agreement with Janssen Pharmaceutica NV, where an affiliate of a former board member is involved.
• Service agreement with Third Rock Ventures for business, technical, financial, IT, or scientific advice.

Stakeholder Impact

• Shareholders: Will vote on director elections and auditor ratification, influencing board composition and oversight.
• Management: Their compensation and employment terms are detailed, with provisions for termination and change of control.
• Auditors: PricewaterhouseCoopers LLP's appointment is subject to ratification, impacting financial reporting assurance.

Next Steps

• Stockholders are urged to vote their shares for the election of directors and the ratification of the independent registered public accounting firm.
• The company will hold its 2026 Annual Meeting of Stockholders on June 10, 2026.
• Stockholders can submit proposals for the 2027 Annual Meeting by December 24, 2026, for inclusion in proxy materials, or by February 10, 2027, to be brought before the meeting.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial results, strategic updates, or material non-public information that would warrant a change in investment recommendation. It primarily concerns governance matters and director elections.

Keywords

Rapport Therapeutics, DEF 14A, Proxy Statement, Annual Meeting, Stockholders, Director Election, Auditor Ratification, Virtual Meeting, Corporate Governance, Emerging Growth Company